Enanta Pharmaceuticals (ENTA) Downgraded by Royal Bank of Canada

Royal Bank of Canada cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from an outperform rating to a sector perform rating in a research note issued to investors on Tuesday morning, MarketBeat reports. They currently have $54.00 price objective on the biotechnology company’s stock.

ENTA has been the topic of a number of other reports. JMP Securities lifted their target price on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, October 4th. Finally, TheStreet raised shares of Enanta Pharmaceuticals from a c+ rating to a b- rating in a research note on Wednesday, December 13th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $45.25.

Shares of Enanta Pharmaceuticals (NASDAQ ENTA) traded down $0.45 during trading on Tuesday, hitting $58.22. 98,100 shares of the stock were exchanged, compared to its average volume of 149,233. The firm has a market cap of $1,122.12, a PE ratio of 66.16 and a beta of 0.64. Enanta Pharmaceuticals has a fifty-two week low of $25.92 and a fifty-two week high of $59.88.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing analysts’ consensus estimates of $2.13 by ($0.27). The business had revenue of $75.93 million during the quarter, compared to analyst estimates of $73.80 million. Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The business’s revenue was up 491.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.09) earnings per share. sell-side analysts forecast that Enanta Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Municipal Employees Retirement System of Michigan increased its stake in Enanta Pharmaceuticals by 3.5% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 110 shares during the period. SG Americas Securities LLC grew its stake in shares of Enanta Pharmaceuticals by 5.8% during the 2nd quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 237 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Enanta Pharmaceuticals by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock worth $1,930,000 after purchasing an additional 304 shares during the period. Thrivent Financial For Lutherans grew its stake in shares of Enanta Pharmaceuticals by 7.3% during the 2nd quarter. Thrivent Financial For Lutherans now owns 8,410 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 570 shares during the period. Finally, Teachers Advisors LLC grew its stake in shares of Enanta Pharmaceuticals by 2.9% during the 1st quarter. Teachers Advisors LLC now owns 25,182 shares of the biotechnology company’s stock worth $776,000 after purchasing an additional 700 shares during the period. 66.83% of the stock is currently owned by institutional investors.

WARNING: This piece was originally published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://weekherald.com/2018/01/05/enanta-pharmaceuticals-enta-downgraded-by-royal-bank-of-canada.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply